Novartis Scemblix® shows superior major molecular response (MMR) rates vs. standard?of?care TKIs in Phase III trial for newly diagnosed patients…
MEDIA & INVESTOR RELEASE
January 8, 2024 – release at 7:30 am CETSophia Antipolis, France
Read the original post:
Nicox : Half-year liquidity contract statement with Kepler Cheuvreux as of December 31, 2023
ORION CORPORATION PRESS RELEASE 8 JANUARY 2024 at 09.00 EET
Here is the original post:
Orion and Glykos announce research collaboration and licensing agreement to develop next-generation ADCs
NeuMoDx CT/NG Assay designed to improve accessibility, affordability and timeliness in sexually transmitted infection (STI) testing in the U.S. // U.S. regulatory clearance of new assay for use on both NeuMoDx 96 and 288 versions of integrated PCR-based clinical molecular testing system // Global presence anchored by 16 EU-certified in-vitro diagnostics (CE-IVD) tests, positioning NeuMoDx as having one of the broadest test menus available to customers NeuMoDx CT/NG Assay designed to improve accessibility, affordability and timeliness in sexually transmitted infection (STI) testing in the U.S. // U.S. regulatory clearance of new assay for use on both NeuMoDx 96 and 288 versions of integrated PCR-based clinical molecular testing system // Global presence anchored by 16 EU-certified in-vitro diagnostics (CE-IVD) tests, positioning NeuMoDx as having one of the broadest test menus available to customers
Essential Pharma acquires European rights to Colobreathe®(colistimethate sodium) from Teva
Go here to read the rest:
Essential Pharma acquires European rights to Colobreathe®(colistimethate sodium) from Teva
Cumulus Oncology raises £9m in seed financing
Visit link:
Cumulus Oncology raises £9m in seed financing
State Alabama Alaska Arizona Arkansas California Colorado Connecticut Delaware Florida Georgia Hawaii Idaho Illinois Indiana Iowa Kansas Kentucky Louisiana Maine Maryland Massachusetts Michigan Minnesota Mississippi Missouri Montana Nebraska Nevada New Hampshire New Jersey New Mexico New York North Carolina North Dakota Ohio Oklahoma Oregon Pennsylvania Rhode Island South Carolina South Dakota Tennessee Texas Utah Vermont Virginia Washington Washington D.C. West Virginia Wisconsin Wyoming Puerto Rico US Virgin Islands Armed Forces Americas Armed Forces Pacific Armed Forces Europe Northern Mariana Islands Marshall Islands American Samoa Federated States of Micronesia Guam Palau Alberta, Canada British Columbia, Canada Manitoba, Canada New Brunswick, Canada Newfoundland, Canada Nova Scotia, Canada Northwest Territories, Canada Nunavut, Canada Ontario, Canada Prince Edward Island, Canada Quebec, Canada Saskatchewan, Canada Yukon Territory, Canada
Zip Code
Country United States of America US Virgin Islands United States Minor Outlying Islands Canada Mexico, United Mexican States Bahamas, Commonwealth of the Cuba, Republic of Dominican Republic Haiti, Republic of Jamaica Afghanistan Albania, People's Socialist Republic of Algeria, People's Democratic Republic of American Samoa Andorra, Principality of Angola, Republic of Anguilla Antarctica (the territory South of 60 deg S) Antigua and Barbuda Argentina, Argentine Republic Armenia Aruba Australia, Commonwealth of Austria, Republic of Azerbaijan, Republic of Bahrain, Kingdom of Bangladesh, People's Republic of Barbados Belarus Belgium, Kingdom of Belize Benin, People's Republic of Bermuda Bhutan, Kingdom of Bolivia, Republic of Bosnia and Herzegovina Botswana, Republic of Bouvet Island (Bouvetoya) Brazil, Federative Republic of British Indian Ocean Territory (Chagos Archipelago) British Virgin Islands Brunei Darussalam Bulgaria, People's Republic of Burkina Faso Burundi, Republic of Cambodia, Kingdom of Cameroon, United Republic of Cape Verde, Republic of Cayman Islands Central African Republic Chad, Republic of Chile, Republic of China, People's Republic of Christmas Island Cocos (Keeling) Islands Colombia, Republic of Comoros, Union of the Congo, Democratic Republic of Congo, People's Republic of Cook Islands Costa Rica, Republic of Cote D'Ivoire, Ivory Coast, Republic of the Cyprus, Republic of Czech Republic Denmark, Kingdom of Djibouti, Republic of Dominica, Commonwealth of Ecuador, Republic of Egypt, Arab Republic of El Salvador, Republic of Equatorial Guinea, Republic of Eritrea Estonia Ethiopia Faeroe Islands Falkland Islands (Malvinas) Fiji, Republic of the Fiji Islands Finland, Republic of France, French Republic French Guiana French Polynesia French Southern Territories Gabon, Gabonese Republic Gambia, Republic of the Georgia Germany Ghana, Republic of Gibraltar Greece, Hellenic Republic Greenland Grenada Guadaloupe Guam Guatemala, Republic of Guinea, Revolutionary People's Rep'c of Guinea-Bissau, Republic of Guyana, Republic of Heard and McDonald Islands Holy See (Vatican City State) Honduras, Republic of Hong Kong, Special Administrative Region of China Hrvatska (Croatia) Hungary, Hungarian People's Republic Iceland, Republic of India, Republic of Indonesia, Republic of Iran, Islamic Republic of Iraq, Republic of Ireland Israel, State of Italy, Italian Republic Japan Jordan, Hashemite Kingdom of Kazakhstan, Republic of Kenya, Republic of Kiribati, Republic of Korea, Democratic People's Republic of Korea, Republic of Kuwait, State of Kyrgyz Republic Lao People's Democratic Republic Latvia Lebanon, Lebanese Republic Lesotho, Kingdom of Liberia, Republic of Libyan Arab Jamahiriya Liechtenstein, Principality of Lithuania Luxembourg, Grand Duchy of Macao, Special Administrative Region of China Macedonia, the former Yugoslav Republic of Madagascar, Republic of Malawi, Republic of Malaysia Maldives, Republic of Mali, Republic of Malta, Republic of Marshall Islands Martinique Mauritania, Islamic Republic of Mauritius Mayotte Micronesia, Federated States of Moldova, Republic of Monaco, Principality of Mongolia, Mongolian People's Republic Montserrat Morocco, Kingdom of Mozambique, People's Republic of Myanmar Namibia Nauru, Republic of Nepal, Kingdom of Netherlands Antilles Netherlands, Kingdom of the New Caledonia New Zealand Nicaragua, Republic of Niger, Republic of the Nigeria, Federal Republic of Niue, Republic of Norfolk Island Northern Mariana Islands Norway, Kingdom of Oman, Sultanate of Pakistan, Islamic Republic of Palau Palestinian Territory, Occupied Panama, Republic of Papua New Guinea Paraguay, Republic of Peru, Republic of Philippines, Republic of the Pitcairn Island Poland, Polish People's Republic Portugal, Portuguese Republic Puerto Rico Qatar, State of Reunion Romania, Socialist Republic of Russian Federation Rwanda, Rwandese Republic Samoa, Independent State of San Marino, Republic of Sao Tome and Principe, Democratic Republic of Saudi Arabia, Kingdom of Senegal, Republic of Serbia and Montenegro Seychelles, Republic of Sierra Leone, Republic of Singapore, Republic of Slovakia (Slovak Republic) Slovenia Solomon Islands Somalia, Somali Republic South Africa, Republic of South Georgia and the South Sandwich Islands Spain, Spanish State Sri Lanka, Democratic Socialist Republic of St. Helena St. Kitts and Nevis St. Lucia St. Pierre and Miquelon St. Vincent and the Grenadines Sudan, Democratic Republic of the Suriname, Republic of Svalbard & Jan Mayen Islands Swaziland, Kingdom of Sweden, Kingdom of Switzerland, Swiss Confederation Syrian Arab Republic Taiwan, Province of China Tajikistan Tanzania, United Republic of Thailand, Kingdom of Timor-Leste, Democratic Republic of Togo, Togolese Republic Tokelau (Tokelau Islands) Tonga, Kingdom of Trinidad and Tobago, Republic of Tunisia, Republic of Turkey, Republic of Turkmenistan Turks and Caicos Islands Tuvalu Uganda, Republic of Ukraine United Arab Emirates United Kingdom of Great Britain & N. Ireland Uruguay, Eastern Republic of Uzbekistan Vanuatu Venezuela, Bolivarian Republic of Viet Nam, Socialist Republic of Wallis and Futuna Islands Western Sahara Yemen Zambia, Republic of Zimbabwe
See the original post:
Ask the doctors: Stem cell treatment for Type 1 diabetes still being researched - ashepostandtimes.com
By Eve Glazier, M.D., and Elizabeth Ko, M.D. Andrews McMeel Syndication
Dear Doctors: My 11-year-old granddaughter was recently hospitalized for two days and diagnosed with Type 1 diabetes. This came as a shock. Her cord blood has been stored since her birth. Is there any way it can be used to help with this disease?
Dear Reader: Diabetes is a disease in which the body is unable to adequately manage blood sugar. It falls into three categories Type 1, Type 2 and gestational diabetes. Although the causes and mechanisms of impaired glucose control differ with each type of the disease, they all involve insulin, a hormone produced by the pancreas. Insulin helps glucose move from the blood into the cells, where it is used for energy.
In Type 1 diabetes, the beta cells of the pancreas are either unable to produce insulin, or they produce very little. This allows glucose to build up in the bloodstream, which is damaging to the body. Treatment of Type 1 diabetes involves the use of injectable insulin, managing diet and close monitoring of blood sugar levels to avoid episodes of low or high blood sugar.
In asking about your granddaughters cord blood, you echo a question that has led to recent groundbreaking research into a cure for diabetes. The focus is on stem cells, which are present in cord blood.
For those who are not familiar, the term cord blood refers to the blood that remains in the umbilical cord and the placenta following an infants birth. It contains stem cells, which are immature cells with the potential to develop into many different types of specialized cells. Stem cells can be used to treat lymphoma, sickle cell anemia, leukemia and some inherited disorders.
Researchers are now studying if the components of cord blood may be useful in treating diseases. This includes cerebral palsy, stroke, spinal cord injury, diabetes, birth asphyxia, age-related cognitive decline and both Type 1 and Type 2 diabetes.
A number of recent studies exploring their use to treat, manage or even cure Type 1 diabetes are yielding promising and sometimes remarkable results. In a small clinical trial in Sweden, certain components of cord blood were used to slow the progression of Type 1 diabetes in newly diagnosed patients. In another study, a biotech firm in San Francisco used genetically altered stem cells to successfully treat mice with Type 1 diabetes. The notable aspect here was that the stem cells were rendered invisible to the immune system, and thus did not provoke an immune response that could have derailed the treatment. At the University of Chicago, researchers used stem cells from cord blood to teach the immune system not to destroy the pancreatic cells that produce insulin.
Although promising, these advances remain in the research phase. There are no stem cell-based treatments for Type 1 diabetes available at this time. However, recent breakthroughs, not only in stem cell therapies, but also in immunotherapy and transplantation of insulin-producing cells, offer real hope for the near future.
Send your questions to askthedoctors@mednet.ucla.edu.
Follow this link:
Ask the doctors: Research being conducted on using stem cells to treat diabetes - The Spokesman Review
NEW YORK, Dec. 29, 2023 (GLOBE NEWSWIRE) -- Cell BioEngines, Inc., a clinical-stage biotechnology company focused on delivering novel, innovative stem cell and immune cell therapies to address blood and solid cancers, today announced an agreement with Miltenyi to develop and manufacture its expanded hematopoietic stem cell transplantation (HSCT) product for clinical use in hematology-oncology.
Cell BioEngines proprietary stem cell expansion technology provides an off-the-shelf curative treatment for blood cancer patients who need a bone marrow transplant. It uses a patented small molecule to increase the number of hematopoietic stem cells derived from umbilical cord-blood while maintaining stemness to address the donor availability for allogenic HSCT.
Under the terms of the agreement, Miltenyi will begin development leading towards Good Manufacturing Practices (GMP) manufacturing of the Phase 1 clinical trial batches of Cell BioEngines CBE-101 clinical program. "Working with Miltenyi enables us to avoid the need to invest time, resources and capital in constructing our own CMC development and manufacturing capabilities. This allows us to concentrate all our efforts on the crucial task of developing and advancing safer, more effective stem cell cancer treatments for patients," said Dr. Ajay Vishwakarma, MBA, Founder and CEO, Cell BioEngines, Inc.
"HSC therapies are particularly well supported through integration of Miltenyis proprietary platforms for cell processing and cell analysis, pre-sterilized single use disposables, as well as Miltenyis best-in-class GMP-quality cell isolation, activation, and culture system reagents. In particular, the CliniMACS Prodigy platform has been developed as an optimized, clinic-ready platform for HSC isolation, transduction, and expansion within a closed, automated system, and for larger-scale allogeneic cell manufacturing processes, Miltenyi has experience in integrating the CliniMACS Prodigy with third-party bioreactors to scale up cell therapy manufacturing processes," said Leonard Pulig President and GM, Miltenyi Biotec, Inc.
"Miltenyi's expertise in cell therapy process development, product scale-up, in addition to accessing state-of-the-art quality systems meeting all US GMP standards for cell therapy products makes them a perfect fit for GMP manufacturing of Cell BioEngines first clinical product candidate," said Alexey Bersenev, MD, PhD, Co-founder and CTO of Cell BioEngines, Inc.
Financial terms of the agreement were not disclosed.
About Cell BioEngines
Cell BioEngines, Inc., is a clinical-stage biotech company focused on developing 'off-the-shelf' allogenic cell therapies as 'drugs' to turn all cancers into curable diseases.The company leverages its proprietaryStem-SPACEplatform technology to produce clinical-grade cells at economies of scale.The companys versatile platform and pipeline allows them to pursue a broad range of cell and gene therapy product candidates in therapeutic areas of interest with high clinical and commercial potential.
About Miltenyi Biotec
Miltenyi Biotec is a global leader innovating products and services that empower biomedical research and advance cellular therapy. The company's solutions support all stages of cell and gene therapy product development from process and analytical development to commercial-scale manufacturing. Its platform technologies have set industry standards in automated, integrated manufacturing and analysis of complex cellular products such as CAR-T cells, TCR-T cells, gene-modified NK and stem cells. Miltenyi Biotecs comprehensive product portfolio is complemented by CDMO services for lentiviral vectors and cell manufacturing. The company has more than 4,700 employees in 23 countries and its products have been used in more than 100,000 cell therapy procedures.
Miltenyi Bioindustry, as a division of Miltenyi Biotec, uses its end-to-end expertise towards developing and manufacturing lentiviral vectors and cell and gene therapy products based on the CliniMACS Prodigy fully automated cell manufacturing platform from pre-clinical to commercial scale.
Contact
Mark Joubert., J.D. Chief Legal Officer Cell BioEngines, Inc. info@cellbioengines.com
A photo accompanying this announcement is available at: https://www.globenewswire.com/NewsRoom/AttachmentNg/6adcbc1f-87dd-42ad-a43d-e45935232982